CRBU
Caribou Biosciences Inc
1.20$
-2.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 120.8% | 55.5% | 29.2% | 24.7% | 1,473.4% | 1,437.8% | 74.1% | 48.7% | 1,019.2% | 17.3% | 27.1% | – | – | |
| -20.8% | 44.5% | 70.8% | 75.3% | -1,373.4% | -1,337.8% | 25.9% | 51.3% | -919.2% | 100.0% | 72.9% | 100.0% | -129.7% | |
| 120.8% | 879.1% | 1,391.0% | 1,024.2% | 1,503.0% | 1,466.7% | 1,510.0% | 1,038.3% | 1,019.2% | 604.3% | 859.9% | 1,263.6% | 854.7% | |
| 41.0% | 273.2% | 602.8% | 331.6% | 293.5% | 505.0% | 413.7% | 390.1% | 418.4% | 217.7% | 336.5% | 526.8% | 336.2% | |
| 41.0% | 1,096.9% | 1,964.6% | 1,331.1% | 515.9% | 533.8% | 1,849.7% | 1,835.3% | 418.4% | 822.0% | 1,169.3% | 1,790.4% | 961.2% | |
| -61.8% | -1,052.3% | -1,893.9% | -1,255.8% | -1,889.2% | -1,871.7% | -1,823.8% | -1,784.0% | -1,337.6% | -722.0% | -1,096.4% | -1,690.4% | -1,090.9% | |
| – | 86.3% | – | – | – | – | – | – | – | – | – | – | – | |
| -42.3% | -964.4% | -1,697.6% | -1,088.3% | -1,713.6% | -1,709.1% | -1,699.6% | -2,028.4% | -1,253.3% | -686.1% | -1,046.5% | -1,619.9% | -1,035.9% | |
| -12.9% | 5.4% | -29.2% | – | – | -0.4% | – | – | – | -14.0% | – | – | – | |
| -42.3% | -969.8% | -1,697.6% | -1,088.3% | -1,713.6% | -1,708.7% | -1,699.6% | -2,028.4% | -1,253.3% | -672.1% | -1,046.5% | -1,619.9% | -1,030.4% | |
| -35.6% | -943.6% | -1,668.3% | -1,063.5% | -1,655.5% | -1,785.8% | -1,650.1% | -1,284.6% | -1,224.6% | -668.8% | -1,019.4% | -1,760.9% | -1,037.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.